Fig. 3: EMT-reversing epigenetic drug screening in organoid cultures. | Nature Communications

Fig. 3: EMT-reversing epigenetic drug screening in organoid cultures.

From: Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition

Fig. 3

a Clustered heatmap of IACS epigenetic drug library screening in T11 and T12 organoids. Drug-treated organoids were assigned a continuous ranking of drug activity (represented by area under the dose–response curve, AUC) for each of the three mapped categories: NEG (no effect, DMSO-like), POS (reduced branching structures, miR-200c induction-like), or MEDIA (no organoid present). Support vector regression was used to fit probability of each class across concentrations, and clustering was done based on these values. The known molecular targets for each drug are shown in the annotation column. The description of each IACS drug is shown in Supplementary Data 1. b Venn diagram showing overlapping top positive-like drug hits and their target categories in T11 and T12 models. BRD bromodomain, HAT histone acetyltransferase, HDAC histone deacetylase, HMT histone methyltransferases, KDM histone lysine demethylase, MLR methyl-lysine reader, PRMT1 protein arginine methyltransferase 1.

Back to article page